Please assess the completion status of the following clinical trial:

Trial Title: PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Relapsed/refractory multiple myeloma~* Progressed or are intolerant of established therapies including proteasome inhibitor, immunomodulatory drug, and anti-CD38 antibody~* Performance Status of 0- 1 ( Performance Score 2 is permitted only if due to underlying myeloma)~* Adequate bone marrow, hematological, kidney and liver function~* Resolved acute effects of any prior therapy to baseline severity~* Not pregnant~Exclusion Criteria:~* Recent history of other malignancies~* History of active autoimmune disorders~* Any form of primary immunodeficiency~* Active and clinically significant bacterial, fungal, or viral infection~* Evidence of active mucosal or internal bleeding~* History of severe immune-mediated adverse event with prior immunomodulatory treatment~* Major surgery within 4 weeks of study treatment start~* Radiation therapy within 2 weeks of study treatment start~* History of stem cell transplant (autologous or allogeneic) within 100 days prior to study enrollment~* Donor Lymphocyte Infusion (DLI) within 30 days prior to study entry~* Less than 30 days since last dose of antibody based therapies or less than 5 half-lives since last dose of previous therapy~* Requirement for systemic immune suppressive medication except as permitted in the protocol~* Current requirement for chronic blood product support

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PF-06863135 (Type: EXPERIMENTAL): BCMA-CD3 bispecific antibody
- PF-06863135 + dexamethasone (Type: EXPERIMENTAL): BCMA-CD3 bispecific antibody + dexamethasone
- PF-06863135 + lenalidomide (Type: EXPERIMENTAL): BCMA-CD3 bispecific antibody + lenalidomide
- PF-06863135 + pomalidomide (Type: EXPERIMENTAL): BCMA-CD3 bispecific antibody + pomalidomide

Based on this trial design, predict the completion outcome and termination type (if applicable).